Latest Content

Aradigm Health’s CEO discusses how payers and other entities in the healthcare ecosystem are developing strategies to ensure cell & gene therapy costs don’t prevent patients from accessing them.

In today's Pharmaceutical Executive Daily, Cellenkos announces FDA clearance of its investigational new drug application for CK0802, BioNTech releases its first quarter 2026 financial results, and Peter Harbin argues that biopharma's longstanding deciling-based sales targeting model is overdue for a fundamental rethink.

FDA clears Cellenkos’ IND for CK0802, enabling a mid-stage trial in steroid-refractory GVHD.

BioNTech reports its first quarter finical results, including losses and declining Covid-19 revenue as the company accelerates its oncology investments and restructures its manufacturing footprint.

Why biopharma's targeting model is overdue for evolution.

Aradigm Health CEO Will Shrank discusses the shift in value-based care models for cell and gene therapies.

Data-driven decision-making, evolving access models, and accelerating adoption of AI create a complex commercialization landscape.

In today's Pharmaceutical Executive Daily, UCB announces a definitive agreement to acquire Candid Therapeutics for up to $2.2 billion, a new commentary by Jeremy Richardson argues that MFN pricing and shifting policy expectations are making affordable direct-to-patient programs at scale an operational necessity rather than a strategic option, and a new article examines how a customer-based process can synchronize sales and marketing organizations for competitive advantage in pharma.

UCB enters agreement to acquire Candid Therapeutics in a deal worth up to $2.2 billion, adding BCMA-targeting T-cell engager cizutamig to expand its immunology pipeline.

Will Shrank, Aradigm Health’s CEO, discusses the importance of transparency in healthcare payments to build trust and reduce waste.

In today's Pharmaceutical Executive Daily, the FDA's Oncologic Drugs Advisory Committee votes a favorable benefit-risk profile for AstraZeneca's Truqap, FDA approves Axsome Therapeutics' Auvelity, and Pharmaceutical Executive speaks with Jeff Golfman on how global disruptions are cascading through the pharmaceutical supply chain.

FDA advisory panel backs Truqap combination in PTEN-deficient prostate cancer, signaling potential expansion into biomarker-defined mHSPC population with limited treatment options.

Jeff Golfman, founder and president of Send 123, in a conversation with Pharmaceutical Executive, discusses how rising geopolitical tensions around Iran and broader global disruptions are reshaping pharmaceutical and medical supply chains.